Evidence map›Paper›PMID 31949554›Full record

ArticleInternational journal of clinical and experimental pathology2018

The antitumor effect of the novel cancer-specific adenovirus Ad-VEGFR on bladder cancer in vitro and in vivo.

Lin Hao, Zhen-Duo Shi, Kun Pang, Hou-Guang He, Rong-Sheng Zhou, Hui Pang, Jun-Jie Zhang, Da-Chuang Liu, Zhuo Sun, Cong-Hui Han

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lin HaoDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Zhen-Duo ShiDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Kun PangDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Hou-Guang HeDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Rong-Sheng ZhouDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Hui PangCentral Laboratory, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Jun-Jie ZhangDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Da-Chuang LiuDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Zhuo SunDepartment of Pathology, College of Biomedical Science, Xuzhou Medical University Xuzhou, Jiangsu, China.
Cong-Hui HanDepartment of Urology, Xuzhou Central Hospital Xuzhou, Jiangsu, China.
Xuzhou Central Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is one of the most common cancers. Approaches that block tumor angiogenesis are a new therapeutic strategy for locally advanced or metastatic BC. VEGF/VEGFR signaling has been obviously and negatively correlated with the progression and invasion of cancer. In this study, we constructed the recombinant adenovirus vAd-VEGFR-3 to investigate its antitumor effector

Indexed as

adenovirusanti-tumor effectBladder cancerbladder mucosa injuryVEGFR

Identifiers

PMID31949554
PMCPMC6962899
OpenAlexW3005632687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.